Arcadia Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
RKDA$0.17+3.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share data)
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $259 | $4,242 |
| Short-term investments | 4,304 | — |
| Accounts receivable and other receivables, net of allowance for credit loss of $559 and $0 as of December 31, 2025 and 2024, respectively | 425 | 1,175 |
| Inventories | 1,212 | 904 |
| Note receivable — current, net of allowance for credit losses (Note 8) | — | 1,894 |
| Prepaid expenses and other current assets | 156 | 931 |
| Current assets of discontinued operations — GoodWheat | — | 96 |
| Total current assets | 6,356 | 9,242 |
| Property and equipment, net | 8 | 41 |
| Right of use assets | — | 137 |
| Intangible assets, net | 39 | 39 |
| Note receivable — noncurrent, net of allowance for credit losses (Note 8) | — | 3,966 |
| Other noncurrent assets | 143 | 92 |
| Total assets | $6,546 | $13,517 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,789 | $2,108 |
| Amounts due to related parties | — | 30 |
| Operating lease liability — current | — | 155 |
| Other current liabilities | 270 | 270 |
| Total current liabilities | 2,059 | 2,563 |
| Common stock warrant and option liabilities | 347 | 2,731 |
| Other noncurrent liabilities | — | 2,000 |
| Total liabilities | 2,406 | 7,294 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value—150,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 1,373,120 and 1,364,940 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | 65 | 65 |
| Additional paid-in capital | 285,292 | 285,036 |
| Accumulated deficit | (281,217) | (278,878) |
| Total stockholders' equity | 4,140 | 6,223 |
| Total liabilities and stockholders’ equity | $6,546 | $13,517 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.